Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO

Chemomab Therapeutics Ltd.

2022-Q3 EPS reported $0.04

Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.
Net loss for Q3 2021 of $3.0M ($0.01/share) vs $1.2M loss in Q3 2020.
R&D expenses $1.5M (up from $1.0M); G&A $1.4M (up from $0.2M) due to public company costs and share-based comp.
Appointed Dale Pfost as CEO and Donald Marvin as CFO/COO; progressing three Phase 2 trials.
Phase 2 data readouts expected: liver fibrosis H1 2022, PSC H2 2022; SSc trial starts early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.